PAVmed Inc. (PAVM)
Market Cap | 10.72M |
Revenue (ttm) | 4.03M |
Net Income (ttm) | 14.72M |
Shares Out | 10.41M |
EPS (ttm) | 0.53 |
PE Ratio | 1.95 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 43,106 |
Open | 0.990 |
Previous Close | 1.020 |
Day's Range | 0.990 - 1.100 |
52-Week Range | 0.600 - 4.875 |
Beta | 0.69 |
Analysts | Strong Buy |
Price Target | 21.00 (+1,938.84%) |
Earnings Date | Nov 13, 2024 |
About PAVM
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, incl... [Read more]
Financial Performance
In 2023, PAVmed's revenue was $2.45 million, an increase of 550.40% compared to the previous year's $377,000. Losses were -$66.27 million, -25.76% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PAVM stock is "Strong Buy" and the 12-month stock price forecast is $21.0.
News
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed In...
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...
PAVmed Inc. (PAVM) Q3 2024 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM) Q3 2024 Earnings Call Transcript November 14, 2024 8:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conferenc...
PAVmed Provides Business Update and Third Quarter 2024 Financial Results
Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The Ohio S...
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
EsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term revenue ...
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Publication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evidence package for submission to formally seek Medicare coverage NEW YORK...
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
Industry veterans from leading cancer detection firm join Lucid to support expansion in fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets NEW YORK ...
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 31, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical tech...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , Oct. 30, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medi...
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
Patent covers proprietary method using methylation of the CCNA1 gene to help detect esophageal precancer and cancer NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lu...
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
Grant will fund research to optimize Veris Cancer Care Platform for medically underserved cancer patients, in partnership with an academic cancer center NEW YORK , Oct. 10, 2024 /PRNewswire/ -- PAVmed...
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed I...
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
Company to showcase EsoGuard® and EsoCheck® at the conference's Innovation Pavilion NEW YORK , Oct. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commerc...
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
Follows the Society's strong endorsement of EsoGuard medical policy coverage by payors NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a com...
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK , Sept.
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening NEW YORK , Sept. 10, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD)...
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK , Sept. 3, 2024 /PRNewswire/ -- Lucid D...
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay NEW YORK , Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Compa...
PAVmed Inc. (PAVM) Q2 2024 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference ...
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer NEW YORK , Aug. 13, 2024 /PRNewswire/ -- Lucid Diagnost...
PAVmed Provides Business Update and Second Quarter 2024 Financial Results
Lucid reports record quarterly EsoGuard® test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's MolDX Program Veris Health actively pursuing financing...
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
EsoGuard® test volume increased 31 percent quarterly; 44 percent annually Clinical data now well-positioned for final push towards broad coverage and reimbursement Over 50 high-volume #CheckYourFoodTu...
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
Event held at Fort Worth Fire Department in partnership with Front Line Mobile Health NEW YORK , Aug. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commer...
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , Aug. 6, 2024 /PRNewswire/ -- Lucid Diagnostic...
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK , Aug. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...